The current price of srulizumab is between $5,000 and $6,000 for adults with advanced solid tumors.
Srolizumab is a self-research tumor immunotherapy drug in China, which belongs to the PD-1 immune drugs.
The main indications approved by the State Drug Administration are microsatellite unstable (MSI-H) solid advanced tumors that have failed the standard regimen and cannot be surgically resected or have developed metastasis.
This includes patients with colorectal cancer who have experienced disease progression after treatment with chemotherapeutic agents.
Patients with advanced gastric cancer who experience disease progression after second-line therapy and for whom there is no satisfactory alternative.
Other solid tumors that have progressed or are not satisfactorily controlled after a first-line treatment regimen.
The use of Srolizumab monotherapy should be under the supervision of an oncologist.